Celonic and IBI-Lorenzini announce a strategic collaboration
Cell line development is one of the most challenging phases, especially when subsequent GMP compliance is required. To boost and support successful commercial introduction of biological drugs to the market, Celonic has developed CHOvolution™, a cell line kit that can be used for a broad range of applications, ranging from non-GMP R&D testing to GMP development and commercial market supply – with a technical and scientific support system to help with every step.
“This agreement is a major step for IBI-Lorenzini. This partnership will strengthen the capabilities of our Biotech Department in the very early phases of the manufacturing process, and will allow us to offer a full service to clients wanting to enter quickly into the clinical phase”, commented Camilla Khevenhueller Borghese, President at IBI-Lorenzini.
Konstantin Matentzoglu, CEO at Celonic AG, added: “I am excited about this truly strategic partnership leveraging an innovative cell line development platform. Together, Celonic and IBI-Lorenzini will provide a safe and proven development platform to clients worldwide.”
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.